Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs

I. V. Lyadova*, H. M. Vordermeier, E. B. Eruslanov, S. V. Khaidukov, A. S. Apt, R. G. Hewinson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

57 Citations (SciVal)

Abstract

Local immune reactivity in the lungs of BALB/c mice was studied following (i) intranasal (i.n.) vaccination with Mycobacterium bovis BCG, (ii) intravenous (i.v.) challenge with a virulent M. bovis field isolate and (iii) i.n. vaccination with M. bovis BCG followed by i.v. challenge with an M. bovis field isolate. The results demonstrated that i.n. vaccination with BCG induced a high degree of protection against systemic M. bovis challenge, and that this protection correlated with a rapid production of IFN-γ after M. bovis challenge by lung T cells from vaccinated mice.

Original languageEnglish
Pages (from-to)274-279
Number of pages6
JournalClinical and Experimental Immunology
Volume126
Issue number2
DOIs
Publication statusPublished - 06 Nov 2001

Keywords

  • Immunity in the lung
  • Intranasal vaccination
  • M. bovis infection

Fingerprint

Dive into the research topics of 'Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs'. Together they form a unique fingerprint.

Cite this